Cell death pathology: The war against cancer

Biochemical and Biophysical Research Communications

Volumn 414, Issue 3, 2011, Pages 445-450

  Rufini, Alessandro ^a   Melino, Gerry ^a,b  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apoptosis; Autophagy; BH3 mimetics; Cancer therapy; P53 family

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 8; ETOPOSIDE; FAS LIGAND; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL X; PROTEIN BID; PROTEIN MCL 1; PROTEIN P53; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN BCL 2; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; MELANOMA; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; HUMANS; IMIDAZOLES; NEOPLASMS; PIPERAZINES; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054912018     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.110     Document Type: Short Survey

References (112)

1. Barbour V. Celebrating death - the 2002 Nobel Prize in physiology or medicine. Lancet 2002, 360(9340):1117.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 44(5):646-674.
3. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999, 17(9):2941-2953.
4. Kroemer G., Galluzzi L., Vandenabeele P., et al. Nomenclature Committee on Cell Death 2009, Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16(1):3-11.
5. Cho H.J., Baek K.E., Park S.M., et al. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011, 10.1016/j.canlet.2011.01.005.
6. Janson V., Johansson A., Grankvist K. Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance. Cell Death Dis. 2010, 1:e78.
7. Bhatnagar 7.N., Li X., Padi S.K., et al. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010, 1:e105.
8. Hervouet E., Vallette F.M., Cartron P.F. Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis. 2010, 1:e8.
9. Tomiyama A., Tachibana K., Suzuki K., et al. MEK-ERK-dependent multiple caspase activation by mitochondrial proapoptotic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death. Cell Death Dis. 2010, 1:e60.
10. Lei W.W., Zhang K.H., Pan X.C., Song D.M., et al. Histone deacetylase 1 and 2 differentially regulate apoptosis by opposing effects on extracellular signal-regulated kinase 1/2. Cell Death Dis. 2010, 1(5):e44.
11. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999, 6(11):1028-1042.
12. Kumar S. Caspase function in programmed cell death. Cell Death Differ. 2007, 14(1):32-43.
13. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407(6805):770-776.
14. Timmer J.C., Salvesen G.S. Caspase substrates. Cell Death Differ. 2007, 14(1):66-72.
15. Tadokoro D., Takahama S., Shimizu K., et al. Characterization of a caspase-3-substrate kinome using an N- and C-terminally tagged protein kinase library produced by a cell-free system. Cell Death Dis. 2010, 1:e89.
16. Inoue S., Browne G., Melino G., Cohen G.M. Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ. 2009, 16(7):1053-1061.
17. Zimmermann K.C., Bonzon C., Green D.R. The machinery of programmed cell death. Pharmacol. Ther. 2001, 92(1):57-70.
18. Li Q.X., Yu D.H., Liu G., et al. Selective anticancer strategies via intervention of the death pathways relevant to cell transformation. Cell Death Differ. 2008, 15(8):1197-1210.
19. Kirkin V., Cahuzac N., Guardiola-Serrano F., et al. The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells. Cell Death Differ. 2007, 14(9):1678-1687.
20. Schulte M., Reiss K., Lettau M., et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007, 14(5):1040-1049.
21. Guardiola-Serrano F., Rossin A., Cahuzac N., et al. Palmitoylation of human FasL modulates its cell death-inducing function. Cell Death Dis. 2010, 1:e88.
22. Van Herreweghe F., Festjens N., Declercq W., et al. Tumor necrosis factor-mediated cell death: to break or to burst, that's the question. Cell. Mol. Life Sci. 2010, 67(10):1567-1579.
23. Matteucci C., Minutolo A., Balestrieri E., et al. Inhibition of NF-κB activation sensitizes U937 cells to 3'-azido-3'-deoxythymidine induced apoptosis. Cell Death Dis. 2010, 1:e81.
24. Melino G., Gallagher E., Aqeilan R.I., et al. Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ. 2008, 15(7):1103-1112.
25. Chan S.W., Lim C.J., Chen L., et al. The Hippo pathway in biological control and cancer development. J. Cell. Physiol. 2011, 26(4):2928-2939.
26. Salah Z., Aqeilan R.I. WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis. 2011, 2:e172.
27. Chang L., Kamata H., Solinas G., et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006, 124(3):601-613.
28. Tomlinson V., Gudmundsdottir K., Luong P., et al. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death Dis. 2010, 1(2):e29.
29. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 2011, 18(9):1487-1499.
30. Mundt H.M., Stremmel W., Melino G., et al. Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem. Biophys. Res. Commun. 2010, 396(2):335-341.
31. Yuan 31.M., Luong P., Hudson C., et al. c-Abl phosphorylation of ΔNp63α is critical for cell viability. Cell Death Dis. 2010, 1:e16.
32. Mitchell G.C., Fillinger J.L., Sittadjody S., et al. IGF1 activates cell cycle arrest following irradiation by reducing binding of ΔNp63 to the p21 promoter. Cell Death Dis. 2010, 1:e50.
33. Falschlehner C., Ganten T.M., Koschny R., et al. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv. Exp. Med. Biol. 2009, 647:195-206.
34. Reis C.R., van der Sloot A.M., Natoni A., et al. Cell Death Dis. 2010, 1:e83.
35. Schneider B., Münkel S., Krippner-Heidenreich A., et al. Gerspach. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis. 2010, 1(8):e68.
36. Liu Y., Lang F., Xie X., et al. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis. 2011, 2:e121.
37. Carlo-Stella C., Lavazza C., Locatelli A., et al. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res. 2007, 13(8):2313-2317.
38. Yin S., Xu L., Bandyopadhyay S., Sethi S., et al. Cisplatin and TRAIL enhance breast cancer stem cell death. Int. J. Oncol. 2011, 39(4):891-898.
39. Thanaketpaisarn O., Waiwut P., Sakurai H., et al. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. Int. J. Oncol. 2011, 39(1):279-285.
40. Schneider-Jakob S., Corazza N., Badmann A., et al. Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid. Cell Death Dis. 2010, 1:e86.
41. Cummins N.W., Badley A.D. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis. 2010, 1:e99.
42. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999, 13(15):1899-1911.
43. Garrido C., Galluzzi L., Brunet M., et al. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006, 13(9):1423-1433.
44. Yivgi-Ohana N., Eifer M., Addadi Y., et al. Utilizing mitochondrial events as biomarkers for imaging apoptosis. Cell Death Dis. 2011, 2:e166.
45. Mace P.D., Shirley S., Day C.L. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ. 2010, 17(1):46-53.
46. Graber T.E., Holcik M. Distinct roles for the cellular inhibitors of apoptosis proteins 1 and 2. Cell Death Dis. 2011, 2:e135.
47. Flanagan L., Sebastià J., Tuffy L.P., et al. XIAP impairs Smac release from the mitochondria during apoptosis. Cell Death Dis. 2010, 1:e49.
48. Joza N., Susin S.A., Daugas E., et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001, 410(6828):549-554.
49. Osato K., Sato Y., Ochiishi T., et al. Apoptosis-inducing factor deficiency decreases the proliferation rate and protects the subventricular zone against ionizing radiation. Cell Death Dis. 2010, 1:e84.
50. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91(2):231-241.
51. Ley R., Ewings K.E., Hadfield K., et al. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ. 2005, 12(8):1008-1014.
52. Fricker M., O'Prey J., Tolkovsky A.M., et al. Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis. 2010, 1:e59.
53. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94(4):491-501.
54. Llambi F., Green D.R. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr. Opin. Genet. Dev. 2011, 21(1):12-20.
55. Tischner D., Woess C., Ottina E., Villunger A. Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis. 2010, 1:e48.
56. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009, 16(3):360-367.
57. Esposti M.D. Bcl-2 antagonists and cancer: from the clinic, back to the bench. Cell Death Dis. 2010, 1(4):e37.
58. Heidari N., Hicks M.A., Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis. 2010, 1:e76.
59. McCoy F., Hurwitz J., McTavish N., et al. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis. 2010, 1:e108.
60. Vogler 60.M., Weber K., Dinsdale D., et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009, 16(7):1030-1039.
61. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435(7042):677-681.
62. van Delft M.F., Wei A.H., Mason K.D., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10(5):389-399.
63. Amundson S.A., Myers T.G., Scudiero D., et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000, 60(21):6101-6110.
64. Goldsmith K.C., Lestini B.J., Gross M., et al. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ. 2010, 17(5):872-882.
65. Placzek W.J., Wei J., Kitada S., et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 2010, 1(5):e40.
66. Tarhini A.A., Kirkwood J.M. Oblimersen in the treatment of metastatic melanoma. Future Oncol. 2007, 3(3):263-271.
67. Wang Y.F., Jiang C.C., Kiejda K.A., et al. Induction of apoptosis in human melanoma cells by inhibition of MEK is caspase independent, and is mediated by the Bcl-2 family members PUMA, Bim and Mcl-1. Clin Cancer Res. 2007, 13:4934-4942.
68. Cragg M.S., Jansen E.S., Cook M., et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 2008, 118:3651-3659.
69. Jiang C.C., Lai F., Tay K.H., et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 2010, 1:e69.
70. Olie R.A., Simões-Wüst A.P., Baumann B., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000, 60(11):2805-2809.
71. Chan K.S., Wong C.H., Huang Y.F., Li H.Y. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis. 2010, 1:e57.
72. Zilfou J.T., Lowe S.W. Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 2009, 1(5):a00188.
73. Melino G., De Laurenzi V., Vousden K.H. p73: Friend or foe in tumorigenesis. Nat. Rev. Cancer 2002, 2(8):605-615.
74. Rufini A., Agostini M., Grespi F., et al. p73 in Cancer. Genes Cancer 2011, 2(4):491-502.
75. Melino G., Bernassola F., Ranalli M., et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J. Biol. Chem. 2004, 279(9):8076-8083.
76. Ramadan S., Terrinoni A., Catani M.V., et al. p73 induces apoptosis by different mechanisms. Biochem. Biophys. Res. Commun. 2005, 331(3):713-717.
77. Schilling T., Schleithoff E.S., Kairat A., et al. Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem. Biophys. Res. Commun. 2009, 387(2):399-404.
78. Gressner O., Schilling T., Lorenz K., et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005, 24(13):2458-2471.
79. Schilling T., Kairat A., Melino G., et al. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2010, 394(3):817-823.
80. Gong G.J., Costanzo A., Yang H.Q., et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999, 399(6738):806-809.
81. Murray-Zmijewski F., Lane D.P., Bourdon J.C. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006, 13(6):962-972.
82. Tomasini R., Tsuchihara K., Wilhelm M., et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 2008, 22(19):2677-2691.
83. Su X., Chakravarti D., Cho M.S., Liu L., et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010, 467(7318):986-990.
84. Wilhelm M.T., Rufini A., Wetzel M.K., et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev. 2010, 24(6):549-560.
85. Candi E., Cipollone R., Rivetti di Val Cervo P., et al. p63 in epithelial development. Cell. Mol. Life Sci. 2008, 65(20):3126-3133.
86. Killick R., Niklison-Chirou M., Tomasini R., et al. p73: a multifunctional protein in neurobiology. Mol. Neurobiol. 2011, 43(2):139-146.
87. Gottlieb E., Vousden K.H. p53 regulation of metabolic pathways. Cold Spring Harb. Perspect. Biol. 2010, 2(4):a00104.
88. Tomasini R., Mak T.W., Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008, 18(5):244-252.
89. Tomasini R., Tsuchihara K., Tsuda C., et al. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc. Natl. Acad. Sci. USA 2009, 106(3):797-802.
90. Levine A.J., Tomasini R., McKeon F.D., et al. The p53 family: guardians of maternal reproduction. Nat. Rev. Mol. Cell Biol. 2011, 12(4):259-265.
91. Cheok C.F., Verma C.S., Baselga J., et al. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011, 8(1):25-37.
92. Zhao M., Duan X.F., Wen D.H., et al. PU.1, a novel caspase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells. Biochem. Biophys. Res. Commun. 2009, 382(3):508-513.
93. McKeller M.R., Herrera-Rodriguez S., Ma W., et al. Vital function of PRELI and essential requirement of its LEA motif. Cell Death Dis. 2010, 1:e21.
94. Flourakis M., Lehen'kyi V., Beck B., et al. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis. 2010, 1:e75.
95. Lam D., Shah S., de Castro I.P., et al. Drosophila happyhour modulates JNK-dependent apoptosis. Cell Death Dis. 2010, 1:e66.
96. Cheng J.P., Betin V.M., Weir H., et al. Caspase cleavage of the Golgi stacking factor GRASP65 is required for Fas/CD95-mediated apoptosis. Cell Death Dis. 2010, 1:e82.
97. Mahmoudi S., Henriksson S., Farnebo L., et al. WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis. 2011, 2:e114.
98. Gonzalez-Mejia M.E., Voss O.H., Murnan E.J., et al. Apigenin-induced apoptosis of leukemia cells is mediated by a bimodal and differentially regulated residue-specific phosphorylation of heat-shock protein-27. Cell Death Dis. 2010, 1:e64.
99. Longatti A., Tooze S.A. Vesicular trafficking and autophagosome formation. Cell Death Differ. 2009, 16(7):956-965.
100. Vellai T. Autophagy genes and ageing. Cell Death Differ. 2009, 16(1):94-102.
101. Liang C. Negative regulation of autophagy. Cell Death Differ. 2010, 17(12):1807-1815.
102. Eisenberg-Lerner A., Bialik S., Simon H.U., et al. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 2009, 16(7):966-975.
103. Kourtis N., Tavernarakis N. Autophagy and cell death in model organisms. Cell Death Differ. 2009, 16(1):21-30.
104. Noda T., Fujita N., Yoshimori T. The late stages of autophagy: how does the end begin?. Cell Death Differ. 2009, 16(7):984-990.
105. Delgado M.A., Deretic V. Toll-like receptors in control of immunological autophagy. Cell Death Differ. 2009, 16(7):976-983.
106. Wirawan E., Vande Walle L., Kersse K., et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis. 2010, 1:e18.
107. Deng L., Feng J., Broaddus R.R. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis. 2010, 1(4):e32.
108. Guo J.Y., Chen H.Y., Mathew R., et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011, 25(5):460-470.
109. Maiuri M.C., Tasdemir E., Criollo A., et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009, 16(1):87-93.
110. Ruela-de-Sousa R.R., Fuhler G.M., Blom N., et al. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis. 2010, 1:e19.
111. Azmi A.S., Mohammad R.M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell. Physiol. 2009, 218(1):13-21.
112. Eldridge A.G., O'Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ. 2010, 17(1):4-13.